US Patent published representing another major milestone in AIBILI’s history (US 11,2354,591 B2)

We are honoured to see our recent US Patent published representing another major milestone in AIBILI’s history. This patent US 11,2354,591 B2 follows the EU Patent EP3289565A1 that was received in August 2020.

The team lead by the inventors José Cunha-Vaz and Torcato Santos have developed a method and device that detects and quantifies abnormal increases of retinal extra cellular space using sites of low optical reflectivity from optical coherence tomography (OCT).

This non-invasive method detects changes in the blood-retinal barrier enabling timely treatment and therapy validation in the early stages of diabetic retinopathy.